Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Molina, 2008, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin Proc, 83, 584, 10.1016/S0025-6196(11)60735-0 Travis, 2013, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J Clin Oncol, 31, 992, 10.1200/JCO.2012.46.9270 Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235 Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X Zhang, 2011, Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial, Lancet Oncol, 13, 466, 10.1016/S1470-2045(12)70117-1 Sun, 2012, Gefitinib versus pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial, Cancer, 118, 6234, 10.1002/cncr.27630 Garassino, 2013, Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial, Lancet Oncol, 14, 981, 10.1016/S1470-2045(13)70310-3 Santarpia, 2011, Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive, Expert Rev Respir Med, 5, 413, 10.1586/ers.11.27 Gazdar, 2009, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, 28, S24, 10.1038/onc.2009.198 Engelman, 2008, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Clin Cancer Res, 14, 2895, 10.1158/1078-0432.CCR-07-2248 Xue, 2012, National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China, Lung Cancer, 77, 371, 10.1016/j.lungcan.2012.04.014 Bremnes, 2005, Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?, Lung Cancer, 49, 1, 10.1016/j.lungcan.2004.12.008 Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8 Zhu, 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21, J Clin Oncol, 26, 4268, 10.1200/JCO.2007.14.8924 Pao, 2007, Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method, Clin Cancer Res, 13, 4954, 10.1158/1078-0432.CCR-07-1387 Kimura, 2006, EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer, J Thorac Oncol, 1, 260, 10.1016/S1556-0864(15)31577-X Kimura, 2006, Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer, Clin Cancer Res, 12, 3915, 10.1158/1078-0432.CCR-05-2324 Jiang, 2011, Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer, J Int Med Res, 39, 1392, 10.1177/147323001103900425 Kim, 2013, Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?, Med Oncol, 30, 328, 10.1007/s12032-012-0328-3 Zhao, 2013, Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients, Respiration, 85, 119, 10.1159/000338790 Goto, 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer, J Thorac Oncol, 7, 115, 10.1097/JTO.0b013e3182307f98 Yung, 2009, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients, Clin Cancer Res, 15, 2076, 10.1158/1078-0432.CCR-08-2622 Sozzi, 2005, Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays, J Natl Cancer Inst, 97, 1848, 10.1093/jnci/dji432 Bai, 2009, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer, J Clin Oncol, 27, 2653, 10.1200/JCO.2008.17.3930 Brevet, 2011, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors, Lung Cancer, 73, 96, 10.1016/j.lungcan.2010.10.014 Taniguchi, 2008, Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib, Cancer Sci, 99, 929, 10.1111/j.1349-7006.2008.00782.x Kimura, 2007, Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA), Br J Cancer, 97, 778, 10.1038/sj.bjc.6603949 He, 2009, Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer, Int J Cancer, 125, 2393, 10.1002/ijc.24653 Liu, 2011, A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients, J Exp Clin Cancer Res, 30, 111, 10.1186/1756-9966-30-111 Chen, 2012, Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib, Oncol Lett, 3, 713, 10.3892/ol.2011.534 Kim, 2013, Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?, Am J Clin Oncol, 36, 57, 10.1097/COC.0b013e31823a5217 Xu, 2012, Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib, Onco Targets Ther, 5, 439 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Zhang, 2012, Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology, Curr Drug Metab, 13, 1007, 10.2174/138920012802138660 Park, 2013, Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib, Clin Lung Cancer, 14, 383, 10.1016/j.cllc.2012.10.007 Bai, 2012, Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer, J Clin Oncol, 30, 3077, 10.1200/JCO.2011.39.3744 Dawson, 2013, Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, 368, 1199, 10.1056/NEJMoa1213261 Suda, 2009, EGFR T790M mutation: a double role in lung cancer cell survival?, J Thorac Oncol, 4, 1, 10.1097/JTO.0b013e3181913c9f Rosell, 2011, Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations, Clin Cancer Res, 17, 1160, 10.1158/1078-0432.CCR-10-2158 Su, 2012, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer, J Clin Oncol, 30, 433, 10.1200/JCO.2011.38.3224 Sakai, 2013, Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor, Cancer Sci, 104, 1198, 10.1111/cas.12211